Methods for Diagnosing and Treating Cancer
AssigneeMassachusetts Institute of Technology
InventorsMichael B. Yaffee, Hans Christian Reinhardt
Life of this patent
Estimating the term…
Loading patent…
AssigneeMassachusetts Institute of Technology
InventorsMichael B. Yaffee, Hans Christian Reinhardt
Estimating the term…
The invention provides methods for decreasing one or more symptoms of cancer in a patient requiring the steps of determining the activation or inactivation of the MK2 signaling pathway and, based on these determinations, administering either a MK2 inhibitor or a combination of a MK2 inhibitor and a chemotherapeutic agent, or a chemotherapeutic agent to the patient. The invention further provides methods for identifying a cancer patient that may selectively benefit from the administration of a chemotherapeutic agent, or the administration of a MK2 inhibitor or the combination of a MK2 inhibitor and a chemotherapeutic agent, requiring the steps of determining the activation or inactivation of the MK2 signaling pathway. The invention additionally provides methods and kits for diagnosing a chemotherapy-sensitive or chemotherapy-resistant cancer in a subject that require the step of (or reagents for) determining the activation or inactivation of the MK2 signaling pathway. The invention also provides methods of treating a cancer patient diagnosed as having a chemotherapy-sensitive or a chemotherapy-resistant cancer.
A method of diagnosing a chemotherapy-resistant cancer in a patient comprising the steps of:
3-6. (canceled)
A method of diagnosing a chemotherapy-sensitive cancer in a patient comprising the steps of:
9-12. (canceled)
16-21. (canceled)
25-27. (canceled)
A method of reducing the severity of one or more symptom(s) of cancer in a patient comprising the steps of:
32-33. (canceled)
35-37. (canceled)
39-40. (canceled)
(canceled)
A method of reducing the severity of one or more symptoms of cancer in a patient comprising the steps of:
49-54. (canceled)
A method of identifying a cancer patient that may selectively benefit from the administration of one or more MK2 inhibitor(s) or the administration of the combination of one or more MK2 inhibitor(s) and one or more chemotherapeutic agent(s) comprising the steps of:
57-62. (canceled)
A method of identifying a cancer patient that may selectively benefit from the administration of dosage of one or more chemotherapeutic agent(s) comprising the steps of:
65-70. (canceled)
A kit for diagnosing a chemotherapy-resistant or chemotherapy-sensitive cancer in a patient comprising:
Dependencies are inferred from the claim text.